Major Adverse Cardiac Events

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

Bypass-first revascularization was associated with significantly higher 30-day MACE (6.9% vs 2.6%; adjusted OR 3.88, 95% CI 2.18-6.88) and 30-day mortality (3.23% vs 1.8%; adjusted OR 2.77, 95% CI 1.2

Effect: adverse; OR 3.88; CI: 95% CI 2.18-6.88

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08

There was no significant difference in adjusted 30-day MALE between bypass-first and endovascular-first revascularization in CLTI patients with infrageniculate disease (9% vs 11.2%; OR 0.73, 95% CI 0.

Effect: null; OR 0.73; CI: 95% CI 0.50-1.08